Anika Therapeutics (ANIK) Q2 FY26 earnings call

Anika Therapeutics delivered a strong second quarter, marked by significant commercial channel revenue growth and substantial gross margin expansion, driven by operational efficiencies and strategic focus on its core HA portfolio. The company raised its full-year outlook across revenue and adjusted EBITDA, reflecting improved execution and profitability, despite adjusting its 2027 revenue forecast to exclude potential Hyalafast US sales due to ongoing regulatory review. Management emphasized continued investment in manufacturing capabilities and pipeline advancement.